{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:23Z","timestamp":1794047423345,"version":"4.8.0"},"reference-count":12,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.282115","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T14:17:51Z","timestamp":1671718671000},"page":"1697-1701","source":"Crossref","is-referenced-by-count":2,"title":["End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET"],"prefix":"10.3324","volume":"108","author":[{"given":"Karan L.","family":"Chohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamad Alhaj","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana N.","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"48800","doi-asserted-by":"crossref","unstructured":"Brockelmann PJ, Sasse S, Engert A. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood. 2018; 131(15):1666-1678.","DOI":"10.1182\/blood-2017-10-772665"},{"key":"48801","doi-asserted-by":"crossref","unstructured":"Johnson P, Federico M, Kirkwood A. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016; 374(25):2419-2429.","DOI":"10.1056\/NEJMoa1510093"},{"key":"48802","doi-asserted-by":"crossref","unstructured":"Andre MPE, Girinsky T, Federico M. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2017; 35(16):1786-1794.","DOI":"10.1200\/JCO.2016.68.6394"},{"key":"48803","doi-asserted-by":"crossref","unstructured":"Straus DJ, Jung SH, Pitcher B. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018; 132(10):1013-1021.","DOI":"10.1182\/blood-2018-01-827246"},{"key":"48804","doi-asserted-by":"crossref","unstructured":"Strobel K, Schaefer NG, Renner C. Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography: is an end of treatment exam necessary in all patients?. Ann Oncol. 2007; 18(4):658-664.","DOI":"10.1093\/annonc\/mdl493"},{"key":"48805","doi-asserted-by":"crossref","unstructured":"Adams HJA, Kwee TC. Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients. Ann Hematol. 2020; 99(1):1-5.","DOI":"10.1007\/s00277-019-03881-x"},{"key":"48806","doi-asserted-by":"crossref","unstructured":"London J, Grados A, Ferme C. Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature. Medicine (Baltimore). 2014; 93(21):e121.","DOI":"10.1097\/MD.0000000000000121"},{"key":"48807","doi-asserted-by":"crossref","unstructured":"Hindi\u00e9 E, Mesguich C, Bouabdallah K, Milpied N. Advanced Hodgkin\u2019s lymphoma: end-of-treatment FDG-PET should be maintained. Eur J Nucl Med Mol Imaging. 2017; 44(8):1254-1257.","DOI":"10.1007\/s00259-017-3714-4"},{"key":"48808","doi-asserted-by":"crossref","unstructured":"Barnes JA, LaCasce AS, Zukotynski K. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011; 22(4):910-915.","DOI":"10.1093\/annonc\/mdq549"},{"key":"48809","doi-asserted-by":"crossref","unstructured":"Chohan KL, Young JR, Lester SC. A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. Blood Adv. 2022; 6(14):4241-4250.","DOI":"10.1182\/bloodadvances.2022007363"},{"key":"48810","doi-asserted-by":"crossref","unstructured":"Mesguich C, Cazeau AL, Bouabdallah K. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol. 2016; 175(4):652-660.","DOI":"10.1111\/bjh.14292"},{"key":"48811","doi-asserted-by":"crossref","unstructured":"Adams HJA, Kwee TC. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis. Eur J Radiol. 2016; 85(11):1963-1970.","DOI":"10.1016\/j.ejrad.2016.08.011"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282115\/75129","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282115\/75683","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10915\/75129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:06Z","timestamp":1794045786000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282115","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}